Medical Devices

CPC of America reports successful preliminary findings in trial for vascular closure device

Published in Medical Letter on the CDC and FDA, December 3rd, 2006

CPC of America, Inc. (CPCF) reports that its subsidiary Med Enclosure, LLC, in its very preliminary findings of the "Randomized, Prospective, Multicenter Trial of the MedClose VCS," produced successful results with no adverse affects reported in diagnostic and interventional studies.

The MedClose VCS (vascular closure device) as a nonsignificant, low risk device determined by both a U.S. independent review board and a Canadian independent review board with subsequent approval by the Canadian Health, Health Products and Food Branch, Therapeutic Products Division for Protocol #CL-7000, is intended to seal femoral arterial puncture sites and reduce time to hemostasis and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-12-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry